Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Heart Test Laboratories, Inc. (HSCS)

1.18   -0.03 (-2.48%) 10-02 22:37
Open: 1.15 Pre. Close: 1.21
High: 1.2495 Low: 1.17
Volume: 11,708 Market Cap: 10(M)
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.25 - 1.26 1.26 - 1.26
Low: 1.15 - 1.16 1.16 - 1.17
Close: 1.17 - 1.18 1.18 - 1.19

Technical analysis

as of: 2022-09-30 4:28:51 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.88     One year: 2.21
Support: Support1: 1.13    Support2: 0.94
Resistance: Resistance1: 1.6    Resistance2: 1.89
Pivot: 1.3
Moving Average: MA(5): 1.2     MA(20): 1.33
MA(100): 0     MA(250): 0
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 9.8     %D(3): 11.3
RSI: RSI(14): 37.4
52-week: High: 6  Low: 1.13
Average Vol(K): 3-Month: 1,259 (K)  10-Days: 75 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HSCS ] has closed above bottom band by 29.9%. Bollinger Bands are 0% narrower than normal.

Headline News

Fri, 30 Sep 2022
Graphdiyne Oxide Effective Against AML Caused by DNMT3A Mutation - AZoNano

Wed, 28 Sep 2022
FDA grants AVR-RD-04 rare pediatric disease designation for cystinosis - Contemporary Pediatrics

Tue, 27 Sep 2022
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress - Yahoo Finance

Mon, 26 Sep 2022
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro - Yahoo Finance

Tue, 20 Sep 2022
Embryo blood cells are stem cell-independent - EurekAlert

Tue, 20 Sep 2022
HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 2.48e+006 (%)
% Held by Institutions 37.7 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.49e+006
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -13
Return on Assets (ttm) 978.3
Return on Equity (ttm) 0
Qtrly Rev. Growth 25170
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -3 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 26380
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.